Regeneron Pharmaceuticals, Inc. (REGN) · Oct 30, 2026 · Earnings
Beat — Non-GAAP EPS $20.07 vs ~$16.1 consensus
Regeneron’s Q3 earnings beat consensus on surging Dupixent, EYLEA HD and Libtayo sales, while raising 2026 margin and R&D outlooks.
Regeneron is in the middle of a commercial transition: Dupixent is scaling rapidly through the Sanofi alliance, EYLEA HD is replacing the older EYLEA franchise, and the company is reinvesting heavily behind a broad clinical pipeline. That setup produced a quarter materially better than the market expected: published estimates clustered around roughly $16.1–$16.4 of non-GAAP EPS and $4.55–$4.56 billion of revenue, versus $20.07 and $5.116 billion reported.
The earnings beat was broad, not just an accounting result. Non-GAAP diluted EPS rose 70% to $20.07, while revenue increased 36% to $5.116 billion; operating income nearly doubled to $2.048 billion from $1.027 billion. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Highlights) | $5,116M (+36%) | $3,754M | ~$4,560M |
| Non-GAAP diluted EPS (Financial Highlights) | $20.07 (+70%) | $11.83 | ~$16.1 |
| Total EYLEA HD + EYLEA sales (Product sales) | $1,741M (-11%) | $1,965M | |
| Libtayo global sales (Product sales) | $550M (+51%) | $365M | |
| Sanofi collaboration revenue (Collaboration revenue) | $2,724M (+68%) | $1,617M |
Dupixent and the Sanofi economics are carrying the growth engine. Regeneron’s share of Sanofi antibody profits jumped to $2.575 billion from $1.456 billion, primarily because of higher Dupixent sales and the end of the development-balance deduction. This is a powerful earnings driver, although part of the step-up was already anticipated after the development balance was fully repaid in the second quarter.
The EYLEA transition is working commercially, but the franchise is not yet growing overall. EYLEA HD sales rose 63% globally to $1.083 billion, but legacy EYLEA fell 49%, leaving combined EYLEA HD and EYLEA sales down 11%. The filing attributes the legacy decline to competition and patient migration to HD, meaning the upgrade is protecting the franchise rather than yet expanding it.
Management raised the quality of the full-year outlook. The company lifted its 2026 gross-margin outlook to approximately 80% GAAP and 86% non-GAAP from 78%–79% and 84%–85%, respectively, while increasing R&D spending by $100 million at both ends of the range. It also lowered the SG&A ranges, implying better operating leverage while continuing to fund pipeline development.
The pipeline and Sanofi deal add longer-term optionality, but they are not yet revenue. Regeneron is advancing roughly 50 clinical candidates and expanded its Sanofi alliance for four next-generation antibodies, receiving a $1 billion upfront payment in the fourth quarter and eligibility for up to $7 billion in milestones. The upfront is meaningful funding for development, but the milestone value remains contingent and future profits would be shared equally.
Bottom line: This was a genuine earnings beat with stronger-than-expected commercial execution and a better margin outlook. The main caveat is that total EYLEA sales are still shrinking during the HD transition, while the biggest new pipeline economics remain several steps from commercialization.
FDA decision on cemdisiran, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!